Baptist Health South Florida

Scholarly Commons @ Baptist Health South Florida
All Publications
2017

The Future of IR: Ascending! Keynote Lecture at the Pairs Annual
Scientific Meeting 2017, Dubai, UAE
Barry Katzen
Baptist Hospital of Miami; Miami Cardiac & Vascular Institute, barryk@baptisthealth.net

Follow this and additional works at: https://scholarlycommons.baptisthealth.net/se-all-publications

Citation
Arab J Intervent Radiol (2017) 1(2):43-8

This Article -- Open Access is brought to you for free and open access by Scholarly Commons @ Baptist Health
South Florida. It has been accepted for inclusion in All Publications by an authorized administrator of Scholarly
Commons @ Baptist Health South Florida. For more information, please contact Carrief@baptisthealth.net.

The Future of IR: Ascending! Keynote Lecture at the Pairs Annual
Scientific Meeting 2017, Dubai, UAE
I cannot tell you what a thrill it was for me to be in here
and an honor (at the Pairs Annual Scientific Meeting 2017).
As someone who has been a passionate about education and
spreading the words so to speak regarding Interventional
Radiology and less invasive therapy, in general, it is really
exciting to see what it is going on in this region, having
sat through lectures yesterday and today again. Everyone
here should be really proud of what is happening right
here in this region. For me, as an educator and someone
who has tried to take the message of those early years and
spread it worldwide, it is a lot of personal satisfaction, so
congratulations.
I was given this title in talking about the future, I will
shorten it a little bit regarding "ascending" and in many
ways, Interventional Radiology, to many people, it's already
arrived, it's already gotten there already. However, actually
to me, it has always been about the future and about where
our platforms can take us and where we are going. People
who work close to me know I live in a window that is about
5 years down the line. It is frustrating to people who are close
to me because sometimes I do not pay attention enough to the
present, and so I am going to try to give a little insight in some
of the big pictures, and there were so many great lectures that
have occurred already in dealing with new technologies and
new approaches to critical limb ischemia (CLI), peripheral
artery disease, and aortoiliac disease. I am not going to dwell
so much on that but try and give you a big picture.
At this year's SIR meeting, there was an interesting talk
given by my Mike Darcy, who is the Dotter Lecturer
this year. As he is talking to his fellows, he gave his
fellows a quiz with some of the big names so to speak of
Interventional Radiology, mixed in with names of famous
performers, artists, musicians, or whatever that was, so
there was Cesare Gianturco and there was a Cesar Romero,
and they had to pick which one is an interventional
radiologist and are they dead or alive and what did they do.
He showed this as part of the Dotter Lecture. I was pretty
pleased to see there were three interventional radiologists
that all of them recognized. I was only recognized by 90%
of the fellows, but the good news is they thought everyone
else is dead, including Ernest Ring, but at least 90%
thought I was alive, so it was good.
In my perspective, I want to change my presentation
today a little to talk a little bit about the past so that you
would understand not only some of greats and how we
got to where we are but also how important step-by-step
technology is and every incremental step we make is an
opportunity for the future. It is only one step moving on
with to the future.

Hence, in talking about this subject, I think it is important
to understand what IR is and I spent a good part of my
career trying to change my identification because, in my
institution, I actually lead the cardiac surgery program
and the interventional cardiology program. We integrated
all services up to a final encounter pathway, but I found
it actually to be unsuccessful and today I think we are
interventional radiologists and so it is best if we train that
way and we, of course, do image-guided procedures that are
therapeutic in nature, but importantly, we provide clinical
care to patients. This is probably the most important thing
we do, and we do it across diverse group of procedures,
which differentiates us from many in Medicine.
We are a discipline that is spread throughout the world, as
you see here in this meeting, offering patients less invasive
solutions to significant medical problems, and we are all
about innovation and change to health care, and that is one
of the things that are different between us and traditional
vascular surgeon, traditional endoscopies, or traditional
anyone that is involved in less invasive therapy. Most
interventional radiologists at their core are looking forward
to change in innovation.
Hence, I think our specialty is generally considered and
has been worn when Charles Dotter, not just did the first
angioplasty that was obviously a very significant event, but
more importantly when he published this first paper and he
talked about two important things; one is using the catheter
as a surgical instrument and so most of us in Intervention
Radiology are, in fact, surgeons. Many of my fellows call
themselves minimally invasive surgeons or endovascular
surgeons in the United States, but importantly from this
little experience, he thought enough to forget all of the
things that you see here in this slide and virtually all of
which has become true.
Hence, if we look at the impact that Interventional
Radiology has had on Medicine, our general space.
Virtually everything on this list has been totally changed
by Interventional Radiology. Some surgery has been
totally eliminated. When I was a radiology resident, the
most common surgical procedure in the United States
was exploratory laparotomy. It is pretty amazing when
you think about it and today, you know, it is unheard of,
we can figure everything out with image-guided biopsies
and sophisticated imaging, feeding problems, peripheral
pulmonary AVMS, uterine fibroids, colonic bleeding,
subarachnoid hemorrhage, and coronary artery disease.
All these are the things that we have had a very dramatic
impact on and, in fact, Vascular and Interventional
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Radiology propelled this entire movement in Medicine
toward less invasive therapies whether it be laparoscopic,
endoscopic, or neurovascular, and many of the people
that came from our early circles in the industry are the
ones that founded these various companies to go out
and create laparoscopic approaches, endo any kind of
approaches.
Hence, we have developed as a specialty over the past
40 years, and in the United States 3 years ago, achieved
subspecialty status, actually specialty status, with
accreditation by the American Board of Medical Specialist.
This has been a scary thing, I note to many of my
colleagues in Europe, who maybe do not agree with this
direction but that is the direction that we, in the United
States, feel really important to define what IR is. Vascular
therapy has been a cornerstone of intervention, but in many
ways, it was just a platform for us to spread out and use
these techniques and other types of applications. When I
started, virtually all cardiac catheterization was done by
radiologist and so, one of the reasons I am particularly in a
place where I am leading the cardiovascular program as I
was old enough to basically have cardiovascular experience
that most radiologists do not today, but that transitioned
of course, and once balloon angioplasty developed, our
cardiology colleagues became much more interested in this
space.
Hence, if we look back in the earlier years of intervention
when the term Interventional Radiology began to develop,
you can look at kind of the procedures that were the "bread
and butter" of procedures, and this is what everybody's
workday looks like. However, things have really
dramatically changed and one of the things I think all of us
understand is that, the procedures that we do today, most
that are important, most of them did not exist 10 years
ago or 12 years ago, you pick the time and so, the nature
of Interventional Radiology, from an educational point
of view, is we have to train our fellows to do procedures
that do not exist. This is to give them the skills, to give
ourselves the skills, and the mental strength to be able to
do things that do not exist because that is our nature.
These are some early papers. You can see in 1979, we were
publishing early balloon angioplasty, I thought I would
share some of these with you for historic purposes in
hypertension in 1979.
Right from the beginning, myself and you will see
Dr. Dake's name, there who was a partner of mine, early
in his career, began to understand that we had to take
this evolving specialty and become significant, not just
be a practitioner; and to be significant, we had to become
a clinical discipline. It was pretty obvious that we were
the only people in Medicine who were not taking care of
our patients. Everybody else is taking care of the patients
that they did procedures on, and coming from a clinical
background myself, it just really did not make any sense.
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Hence, we began to write along with others about the
importance of clinical training.
Finally in the United States, we see this actually being
formally structured as the US training pathways are
changing. As you know, there is going to be a residency
in Interventional Radiology now, meaning the fellowship
are going to go away, and these residencies are going to
include time in critical care, time on the floors, and clinical
management, and refreshing the skills or adding to the
skills that we need.
Today, in modern IR, hospitals at least in the United States
cannot function without an interventional radiologist or
more, and there are hospitals that have lost their IRs over
turf battles and things like that, and they have been written
up in journals and created emergencies for patient care. It
is really pretty amazing how we are woven into the metric
of day-to-day practice.
Again, Interventional Radiology has accomplished so
much. If you were to look at the curriculum vitae of our
specialty and what we have accomplished whether it is in
peripheral arterial disease, cancer treatment, palliative care,
and treatment of aneurysms. However, things have changed
over the past 20 years, and what we have found is that we
have developed and we practised procedures that other
people want to do and the people who want to do them
are the disease management doctors. They are, you know,
somebody who was trained on how to take care of vascular
disease and want to be able to do the procedures associated
with taking care of his or her patients and so this has been
a challenge for our discipline. We have been able to figure
it out in Miami and survived in a significant way.
It has been a challenge to IR as we have been unable, in
many cases, to hold on to our innervations.
Hence, I just want to talk a little bit about some megatrends
and challenges. Now, instead of being a developing field,
endovascular therapy is really a mature field. It is very
broad. It is very important for us to define who benefits
and bring science to this discipline. Some of them were
cardiology and vascular surgery.
One of the other megatrends has been the effect of
computed tomography angiography and magnetic resonance
angiography, so our trainees no longer have diagnostic
angiography to use as a platform for developing basic
catheter skills. They are expected just as surgeons to go
from zero into doing some sort of complex recanalization;
it is pretty challenging from a training and educational
point of view. We obviously are defining now the role
and methods of drug delivery, and we are experiencing a
worldwide in epidemic CLI.
Hence, it is uncommon in us, especially in these regions and
other regions of the world, to make endovascular therapy
more cost-effective and less expensive both, and how are we
going to do this. I am going to talk more about amputation
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rates and some of the public health issues, but more and
more, Interventional Radiology is challenged now to produce
proof of our procedures. When we did the first angioplasty,
it was pretty intuitive, "Wow! This patient can walk now
and did not need surgery." Well, that no longer gets us
anywhere and the compelling need for data in clinical trials
is important and you will hear that I talk about our failures
and some of the new procedures that you will see here are
going to need data and proof before our colleagues accept it.
We look at endovascular as very broad, so to me treatment
of an AVM is endovascular, pretty much anything if we
take the number 2 broad definition and how we, ourselves,
are organized, and it is any discipline, any organ system,
anything that involves image-guided therapy. However,
others can look at it in a different way, they can look at it,
to many vascular surgeons, endovascular means aortic work
and somehow peripheral intervention means something
different. Hence, we still have a lot of definitional issues
within the entire space.
If we look at IR today, specifically endovascular therapy
has replaced much traditional vascular surgery, but it
has also become cardiovascular surgery. In the United
States, about 30 percent of this is done by interventional
radiologist and has become a multidisciplinary field. That
is just the way it is, it is steady but it is multidisciplinary,
and so interventional radiologists, among other things,
needs to learn how to compete.
With endovascular therapy, we can do a lot of things,
opening vessels, closing vessels, and treating cancer; it is
all part of using the circulation as a therapeutic conduit
The pioneers in this space really started in the 60's; these
are Stanley Baum and Josef Rosch, who unfortunately
both passed away and the concept of using the catheter for
surgical tool, in this case to deliver drugs, was developed
by them. The concept of trying to get a balloon to make an
artery bigger than the catheter itself is generally credited to
Werner Porstmann who, at that time, was behind the iron
curtain in Charite Hospital in East Berlin, and I thought I
would share this with you, this is actually the first patient
I treated in Rome; it was in 1974, and I am the one with
the beard and the big hair along with the others, but this
patient did incredibly well with that corset catheter for 6 or
7 years we had angios on this patient, it was amazing what
could be done and this is what fired our whole discipline,
followed by Gruentzig who developed the technology to
reach his dream of treating coronary arteries, and along the
way, incorporated the vascular system as well, and then, a
group of people took the next step which was opposed by
Dotter actually of managing thrombus and managing the
clot with a catheter and then stents came along, and the
thing about these and the reason that I am going through
this is that each of these was one step going to the next.
Hence, stents were interesting as you can see, but maybe
there were more important to develop a platform for

endografts and the concepts of endografts or the concept of
drug delivery. Much more important, drug delivery or the
stent and so each of these incremental concepts were very
important in moving our field forward.
Now, we still have a ways ago, people are dying of
aneurysms. These are some of the well-known people that
have passed away from ruptured aneurysms. Some of them
knew they had aneurysm, some of them did not and we
know that aneurysms can occur everywhere, and of them
we knew had them some of them we did not, we know that
we have made a great stride here but also we have taken
something that was an idea and made it standard of care.
And so, each of these areas that we have touched on, we
have actually made standard of care and each and every
one of you are part of a field that should take great pride in
that. It has not all been perfect and one of the things you
have to know about innovation is that innovation involves
failure, and these are some of the devices that have failed.
Some types they fail early, some types they fail late, but
we have to be careful when we talk to our patients, in
particular, to be intellectually honest about what we know
and what we do not know and some of the devices, I am not
sure if some others which have failed. However, where are
we trying to take endovascular aneurysm repair (EVAR)?
The fact that we can treat an aneurysm less invasively, that
is not the end-game; that is the beginning. The end-game is
for patients to be able to come in, have their aneurysm fixed
and go home the same day. That is dramatically changing
in the way healthcare is delivering. We have been very
interested in this for a long time, and it is not just going to
involve the technology or the right piece of equipment, it is
going to involve a total change in how we manage patients
and how we get paid for patients. In the United States for
instance, if you were to treat a patient as an outpatient, you
cannot get paid; it is required to be an inpatient, as a result,
this particular study, the LIFE study was done on inpatients
that simulated outpatients, and they all had percutaneous
access, no general anesthesia, no ICU and were pushed for
next-day discharge with 250 patients and this was recently
presented at ISET and has been presented in other meetings
as well, and you can see that comparing it to that analysis
as traditional EVAR, that there was great safety, reduced
procedure time. The length-of-stay was 1.2 days because
we were not allowed to send them home basically during
the course of this trial, and importantly, the readmission rate
was much, much lower at 30 days than traditional EVAR
patients, so there was no intent to push these patients out
only to have them be readmitted in a short period.
Here, you can see the performance goal in terms of major
adverse event (MAE) rates, and you can see that of the
250 patients in a so-called fast track, there was only one that
had any type of MAE and that was a readmission in 30 days.
Along the way, you are going to hear more about during
this meeting. As image-guided therapist, imaging has been
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of significant improvement to us as we can combine what
used to be just looking at a flat screen like this and learning
how to do this in our heads to be being able to superimpose
3D models, and this is not just for the uneducated or
people that are not radiologists. This technology is making
all of us better by able to see precisely and understand
what we are doing and nowadays with image fusion, we
can actually move the table and around rotate and keep
everything synced up and so for doing very complex cases,
it has really been a significant improvement.
One of the important areas of Interventional Radiology
that is becoming more important is the issue of CLI, and
there were a lot of talks yesterday, great talks about how
to treat CLI but I am not going to talk about that. What I
want to talk about is CLI as a disease and point out that
25% of our patients with CLI are going to be dead in
12 months, probably 70% are going to be dead in 3 years
and so similar to what we did when we started treating
SFA disease, it is really important that if you are thinking
about developing a CLI program, that you start thinking
about the patient as a whole, not just of the wound and
yesterday, we saw some cases where revascularization
was made but the patient lost their leg because of lack of
teamwork and lack of combined therapy that is necessary.
Hence, we know that is an epidemic and pandemic and
we think that there is a great opportunity from the public
health point of view.
Now, all ideas are not just technology. We have some great
thinkers in our space, one of them being Dr. Manzi, who is
on the program this year who thought about approaching
things on these very tiny arteries in the foot that most
of us thought were impossible. In fact, I heard someone
yesterday during the comment section, and the idea of
combining retrograde and antegrade access to accomplish
something which could have been a failure before or to
avoid failure is an example of how creative interventional
radiologists are in creating unique solutions.
In this particular case, I think by now probably all of you
had experienced here, you can act up immediately and it is
very helpful in this particular case, myself and my vascular
surgical colleagues are working together, and teamwork is
very important to get greater results here.
Hence, all ideas and not technology or many of them,
especially in CLI, come from our brains without a lot of
expensive thought or technology. Hence, what is CLI? Well,
we did a survey in the United States and if you survey 10
people what CLI is, you get 10 different answers, and what
that means in the United States at least is that we cannot
get paid for it. Hence, if a patient comes in with CLI and
we are trying to figure out how much does it cost to take
care of a patient with CLI, it is very, very difficult because
there are no codes, there is no identification, and we are
very interested in developing a CLI program to prolong life
and reduce amputations.
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So for instance, if you were to look a Rutheford 6, these
are three different feet. They certainly do not have the same
probability of success in terms of saving that foot and yet,
right now, we do not have any way of really classifying
those differences, and so there is really a critical need to
do that.
Recently, in the United States, the Society of Vascular
Surgery has proposed the W1FI system, which would allow
us to be able to differentiate what the classifications are.
What we know is that 50% of the patients that actually
get revascularization, 25% are going to be dead in a year,
30% are still going to have amputations of some sort, and
only 25% are going to have their CLI resolved. Hence,
interventional radiologists want to look for opportunity. We
generally want to create procedures and technologies that
fill gaps but to do that for CLI, we need to develop metrics
for success, and we need a definition of patient population.
If you compare us to ST-segment elevation myocardial
infarction, for instance, in acute myocardial infarction,
we are so far off of the metrics necessary to really make
an impact on CLI and that there is a lot of work to do.
And so, this year at ISET, myself and a number of others
announced the formation of the CLI Global Society. Those
of you who are involved in this hopefully will get involved
in this phase, but this is not a society that has meetings and
things like that. The mission is to improve the quality of
life by preventing amputations and death due to CLI, so we
actually want to take that mortality rate and lower it. We
want to take amputation rates country by country and lower
it, similar to what the American Heart Association has been
doing for cardiac mortality.
The next technology I want to briefly talk about are things
that are going to be important. We know about drug-eluting
balloons and drug-eluting stents, but Bioabsorbable
Scaffolds are the next hot thing, leaving nothing behind
and a lot of people believe this is the next great thing.
However, in the past year, it has become clear that there
are significant issues related with this technology that is
probably going to bring some caution. One is that generally,
they require OCT to be able to determine whether you got
good wall apposition. Most interventional radiologists do
not have OCT as an integral part of the laboratory. That
also means slow cessation to be able to image it. However,
the imaging is exquisite of course. I think it is certainly
true that device-drug combinations are ultimately going to
be part of what we treat all patients with, in my opinion,
but I think regarding Bioabsorbable, all we can say is that
they may play a role today but they are not the answer yet.
Now, I mentioned also that in pushing for change and
pushing for innovation, we have made some mistakes
and we have some procedures that have failed and they
have had an impact on failure and this year at SIR, two
important trials were released. One is the kr fRACT trial
which is a randomized trial of iliofemoral thrombolysis.
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There are a lot of problems with this trial by the way, but
the end-point was venous stasis syndrome and it turned out
to be no difference at 2 years. Morever, the other one was
on multiple sclerosis.

of acute right heart failure generally. They die reflexively
and deal of acute right heart failure. Hence, these are
potential life-threatening initiatives, and the development
of pulmonary embolism response teams is a big initiative.

How many people remember what the frenzy was like
5 years ago with centers opening up, many of them in this
region to treat these patients, and now what is happening is
too many interventional radiologists were really unfortunate
carrying the flag on this. Most of us were skeptical but
others were not, and a lot of patients got procedures they
did not need as a result.

There are some other out-of-box applications I think you
are aware of, prostatic embolization. People are very, very
excited about that. We can see the prostate shrink. How
could this possibly not work? How could CCSVI not
work? How could any of these other things not work? We
need clinical data and we need trials and those of us in the
space should be demanding it, same thing with left gastric
embolization for morbid obesity. Very exciting!

Renal denervation is another example. Multibillion dollars
spent on technology and then a single trial which was
misinterpreted, in my opinion, more or less killed an entire
space of research which continues on.
Hence, how about isolated organ perfusion? Anybody
involved with that? I think there were some in this region
that were great promise, probably the wrong drug, the
wrong cancer, and it wound up being a failure. So as IRs
matured, we know that there have been some failures that
we have had and we have to be prepared for that.
Now, what final thing I want to mention is what about
threats to us. Well, we may not have heard about Tom
Lawson, he is a scientist. He used to be at Duke University,
but I think he left to join this company. However, he
basically figured out how to manufacture artificial blood
vessels, and they are actually being put in patients in
Eastern Europe now.
Now, if you can make a blood vessel and you can deliver
drug out of that blood vessel, you know, then think about
that as it relates to stents and the things we do. This could
be a potential game-changer for all of us.
Robotics, I think you all know what happened to robotics.
Unfortunately, myself and Professor Hamady, we believe
that there is a future there but I am not going to dwell on
it because of recent events, but we do believe that there is
an opportunity.
And then finally, I think, on a positive note, what are the
next great areas that we are going to be involved in and
one of the big emphases is now on pulmonary embolism.
It is a very common cause of death in hospitalized patients,
and there is big initiative that is welled up now to look
at submassive and massive pulmonary embolism and the
role of interventional therapy. These are very dramatic
things. In this particular patient, a catheter was put in the
main pulmonary artery, just maceration by spinning the
catheter followed by catheter-directed lysis in this case
with ultrasound enhancement and you can see the images
on the lower right. But most importantly, if you look at the
right ventricle-to-left ventricle ratio before and after, you
can see that this has had very significant effect on cardiac
function. The reason that patients with PE die is because

Then, finally, Interventional Oncology this is the great
savior of Interventional Radiology. I gave a talk at a
guest meeting 2 years ago on the death of Interventional
Oncology, so the same thing can happen if we do not
embrace clinical management of patients. Hence, if you
look at this, this is clinical Interventional Radiology,
technology, and multidisciplinary care has to interact.
Hence those of you, who are engaged in this space, need
to be able to be prepared to learn a lot about cancer, a
lot about longitudinal management. This is not just about
picking the right way to kill a cancer focally but managing
the morbidity long term as a result of that. When you
start giving radiotherapy in any type of way, you need to
be prepared to manage those patients longitudinally and
prospectively in terms of providing input on patient safety
and long-term morbidity.
We know that our space is seeing a lot of imaging, you can
hear more a about that, and the final thing that I want to
share with you is this idea:
What if you can put in stent in someone and when that
stent starts narrowing, you get a warning on your iPhone
or in your office that that stent is starting to fail. Well, this
is the technology we are beginning to look at in the case
of both bypass grafts in this model for dialysis fistulas.
This was also presented at ISET that first-in-man trials
are getting ready to be run. But you can see, here is the
input on animals who had dialysis grafts put it and then
a stenosis was created, you can see the follow-up on the
image on your lower image.
While for most of us interested in bypass graft is less, they
can manufacture and put this piezoelectric sensor actually
into a multisegmented stent which, in theory, could provide
us feedback and reduce the need for a lot of other studies
and then send the signal back to an iPhone.
So what about the future? Well, for those of you living
and working in this region, I tried to get some specific
information, and this is a transient forecast on the business
side of things and will forecast out through 2024.
In the inner core, there is the Middle East and Africa, the
smaller one, which I think is actually an underestimation
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but you can see the relative growth in different regions
of the country but I think this is a global mix of different
types of cases and given our impact on medicine, I see no
way that it is not going to grow significant in this region.
If you look at this business analysis in terms of where
that growth is going to occur, a lot of us projected in still
in arterial lower extremity revascularization, it is the big
bubble just above coronary there, in this region as well, as
well as venous intervention and then, there are some other
AAA recurrence so on by the smaller bubbles.
Hence, think about it, how many procedures do you do
today that you did 10-15 years ago? Probably, a lot but
you did not do, most of them are new. What are you going
to be doing 10 years from now? Likely, new procedures
that are being developed and I would mention a little bit,
but are being proven today and one of the things you need
to worry about is creating the environment to do these
procedures better and especially here in an environment
where things are very cost sensitive and we rely on
expensive technology. Hence, we need to work together
with our industry partners to figure out all the solutions to
provide such valuable care to patients that you take care
of or patients that you need without unlimited capital. You
know, it is definitely a challenge because we have a better
way to take care of patients than the status quo.
Hence, I say, continued growth worldwide driven
by technology and ideas that are going to continue
innovation, Interventional Radiology is going to begin
to prove cost efficacy. In the United States even, we are
on a huge pressure to every clinical trial we do, has to
have a health-care economics model to it and the FDA is
starting to require cost-benefit not just a clinical benefit. As
technology gets more broadly adaptive, cost will decrease
but also competition is going to increase and training of
the next generation interventional radiologist will continue
to be difficult because of the change in procedural mix that
we are constantly facing.
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Hence, in conclusion, we are very excited to be part of a
growing specialty of medicine which impacts virtually every
disease process wherever you live. There is some disease
that is going on that we can help. It is interesting that it is
junction between technology and disease as where we sit led
by physicians who are interested in changing that status quo,
not simply diagnosing and treating disease. As we grow as
a specialty, filling more clinical services will be expected by
others, they are going to expect us to care of these patients and
remain necessary to compete as well with disease management
specialists who are interested in doing the same procedures.
Hence, with that, I thank you very much for your attention.
I hope some of you might be able to come and visit us next
year in Miami or South Florida and thank you very, very
much for your attention.
Barry T Katzen
FIU Herbert Wertheim College of Medicine, Miami Cardiac and
Vascular Institute, Baptist Hospital of Miami, Miami, FL 33176, USA.
E-mail: Btkatzen@aoLcom
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